Yescarta

Yescarta, with the generic name axicabtagene ciloleucel, is a CD19-directed autologous chimeric antigen receptor (CAR) T-cell therapy developed by Kite Pharma (a member of Gilead Sciences) for certain B-cell non-Hodgkin lymphomas. It is designed for use in adults whose disease is relapsed or refractory after prior systemic therapy.

Mechanism and manufacturing. The therapy uses the patient’s own T cells, collected by leukapheresis. These cells are genetically modified to express a CAR that recognizes CD19 on B cells, then expanded and cryopreserved. After a lymphodepleting chemotherapy regimen, the CAR T cells are infused back into the patient. In the body, the engineered T cells target and destroy CD19-positive B cells, including malignant lymphoma cells.

Indications. In the United States, Yescarta is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The exact indications can vary by jurisdiction and over time as regulatory approvals expand or shift.

Administration and safety. Yescarta is given as a single infusion following conditioning chemotherapy, and patients require close monitoring for several weeks after infusion. Serious adverse events include cytokine release syndrome (CRS) and neurologic toxicities, which can be life-threatening. Other potential risks include cytopenias, infections, and organ toxicities. Management may involve supportive care, tocilizumab for CRS, and corticosteroids for severe neurologic events. Access is typically through certified centers under a risk-management program.

Efficacy and considerations. In pivotal trials, Yescarta demonstrated meaningful response rates in eligible patients, with responses that can be durable for some individuals. The therapy represents a targeted, cell-based approach that has influenced subsequent development of CAR T-cell treatments for hematologic cancers.

See also. Other CAR T-cell therapies for B-cell malignancies include products such as Kymriah and Tecartus.